Cargando…
Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor
Osteonecrosis is a pathological condition that could lead to a debilitating physical disease and impede daily activities. It is generally categorised into aetiology – primary (idiopathic) or secondary. When direct damage to the bone vasculature or direct injury of the bone marrow is related to an id...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366292/ https://www.ncbi.nlm.nih.gov/pubmed/30783528 http://dx.doi.org/10.1177/2050313X19827747 |
_version_ | 1783393602106294272 |
---|---|
author | Haydock, Maria Monica Elhamdani, Shahed Alsharedi, Mohamed |
author_facet | Haydock, Maria Monica Elhamdani, Shahed Alsharedi, Mohamed |
author_sort | Haydock, Maria Monica |
collection | PubMed |
description | Osteonecrosis is a pathological condition that could lead to a debilitating physical disease and impede daily activities. It is generally categorised into aetiology – primary (idiopathic) or secondary. When direct damage to the bone vasculature or direct injury of the bone marrow is related to an identifiable cause such as traumatic injuries, steroid or bisphosphonate use, increased alcohol intake, sickle cell disease, autoimmune diseases, chemotherapy or malignancy, it is categorised as secondary osteonecrosis. On the other hand, osteonecrosis wherein the mechanisms of development are not fully understood is categorised as primary or idiopathic osteonecrosis. This category includes inherited thrombophilia and hypofibrinolysis as potential causes. There are no clear guidelines or general agreements about anticoagulation treatment and duration in primary osteonecrosis due to thrombophilia or hypofibrinolysis. We report a case of primary osteonecrosis associated with hypofibrinolysis and successful control with lifelong direct oral anticoagulation therapy. |
format | Online Article Text |
id | pubmed-6366292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63662922019-02-19 Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor Haydock, Maria Monica Elhamdani, Shahed Alsharedi, Mohamed SAGE Open Med Case Rep Case Report Osteonecrosis is a pathological condition that could lead to a debilitating physical disease and impede daily activities. It is generally categorised into aetiology – primary (idiopathic) or secondary. When direct damage to the bone vasculature or direct injury of the bone marrow is related to an identifiable cause such as traumatic injuries, steroid or bisphosphonate use, increased alcohol intake, sickle cell disease, autoimmune diseases, chemotherapy or malignancy, it is categorised as secondary osteonecrosis. On the other hand, osteonecrosis wherein the mechanisms of development are not fully understood is categorised as primary or idiopathic osteonecrosis. This category includes inherited thrombophilia and hypofibrinolysis as potential causes. There are no clear guidelines or general agreements about anticoagulation treatment and duration in primary osteonecrosis due to thrombophilia or hypofibrinolysis. We report a case of primary osteonecrosis associated with hypofibrinolysis and successful control with lifelong direct oral anticoagulation therapy. SAGE Publications 2019-02-04 /pmc/articles/PMC6366292/ /pubmed/30783528 http://dx.doi.org/10.1177/2050313X19827747 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Haydock, Maria Monica Elhamdani, Shahed Alsharedi, Mohamed Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
title | Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
title_full | Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
title_fullStr | Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
title_full_unstemmed | Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
title_short | Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
title_sort | long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366292/ https://www.ncbi.nlm.nih.gov/pubmed/30783528 http://dx.doi.org/10.1177/2050313X19827747 |
work_keys_str_mv | AT haydockmariamonica longtermdirectoralanticoagulationinprimaryosteonecrosiswithelevatedplasminogenactivationinhibitor AT elhamdanishahed longtermdirectoralanticoagulationinprimaryosteonecrosiswithelevatedplasminogenactivationinhibitor AT alsharedimohamed longtermdirectoralanticoagulationinprimaryosteonecrosiswithelevatedplasminogenactivationinhibitor |